{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:10:47Z","timestamp":1792156247499,"version":"4.4.0"},"reference-count":67,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The year 2025 has been transformative in breast oncology, marked by the maturation of pivotal adjuvant trials, the introduction of novel ADCs, and the validation of proactive biomarker-driven strategies across all molecular subtypes. ASCO, ESMO, and SABCS contributed pivotal updates that further refined treatment paradigms. This systematic review synthesizes and critically evaluates pivotal Phase II\/III clinical trials presented at major oncology conferences (ASCO 2025, ESMO 2025, SABCS 2025) and published in high-impact journals during 2025. A curated selection of pivotal Phase II\/III trials, and major prospective trials published or presented in 2025 was performed. Data extraction focused on trial design, population, interventions, efficacy endpoints, and safety outcomes. Narrative synthesis was organized by disease stage and molecular subtype. Key 2025 findings (50 clinical trials) include: (1) confirmation of overall survival benefit with adjuvant CDK4\/6 inhibitors in HR+\/HER2\u2212 early breast cancer (monarchE: HR = 0.842, p = 0.0273); (2) establishment of trastuzumab deruxtecan (T-DXd) as a new standard in high-risk HER2+ early disease (DESTINY-Breast05: IDFS HR = 0.47) and first-line metastatic settings (DESTINY-Breast09: PFS HR = 0.58); (3) validation of TROP2-directed ADCs as first-line therapy for metastatic triple-negative breast cancer (ASCENT-03: PFS HR = 0.62; BEGONIA: ORR 79%); (4) paradigm shift to proactive, liquid biopsy-guided therapy switching (SERENA-6: PFS HR = 0.44); (5) updated efficacy and safety of the oral SERD imlunestrant from the EMBER-3 trial, supporting its role in ESR1-mutated advanced breast cancer and in combination with abemaciclib; (6) confirmation of long-term survival benefit for neoadjuvant carboplatin in early TNBC and new positive adjuvant data; (7) pivotal advances in HER2+ metastatic disease sequencing with tucatinib and T-DXd; (8) evidence supporting optimized adjuvant endocrine therapy in HER2+\/HR+ early disease; and (9) emergence of novel agents with improved therapeutic indices, including PROTAC degraders, oral SERDs, and mutant-selective PI3K inhibitors. The 2025 evidence base has fundamentally reshaped breast cancer management, establishing new standards of care across all subtypes. Unifying themes include biomarker-driven personalization, strategic treatment sequencing, management of unique toxicities, and emphasis on patient-reported outcomes. Future challenges include optimizing treatment integration, managing financial toxicity, and ensuring equitable global access.<\/jats:p>","DOI":"10.3390\/ijms27041971","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:51:09Z","timestamp":1771491069000},"page":"1971","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5786-5134","authenticated-orcid":false,"given":"Nabil","family":"Ismaili","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Casablanca 82403, Morocco"},{"name":"Mohammed VI Foundation of Sciences and Health (FM6SS), Casablanca 82403, Morocco"},{"name":"Oncopathology, Biology and Environment of Cancer Laboratory, Mohammed VI Center for Research and Innovation (CM6RI), Rabat 11103, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105858","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/j.annonc.2025.08.725","article-title":"296O Risk of recurrence (ROR) after neoadjuvant ribociclib plus ET in clinically high-risk ER+\/HER2\u2212 BC: Preliminary analysis of the SOLTI-RIBOLARIS trial","volume":"36","author":"Cottu","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104987","DOI":"10.1016\/j.esmoop.2025.104987","article-title":"415O Predictive factors of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in the POSITIVE trial","volume":"10","author":"Demeestere","year":"2025","journal-title":"ESMO Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/j.annonc.2025.08.723","article-title":"294MO Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)\/human epidermal growth factor receptor 2-negative (HER2-) and Ki67\u2265 10% early breast cancer (EBC): The EMPRESS study","volume":"36","author":"Viale","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_9","first-page":"CD-25-0001","article-title":"Neoadjuvant vepdegestrant (ARV-471) in postmenopausal patients with ER+\/HER2\u2212 early breast cancer: Primary results from the phase 2 TACTIVE-N trial","volume":"15","author":"Jhaveri","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bardia, A., Schmid, P., Mart\u00edn, M., Hurvitz, S., Jung, K., Rimawi, M., Saji, S., Werutsky, G., Harbeck, N., and Loi, S. (2025, January 9\u201312). Giredestrant vs Standard-of-Care Endocrine Therapy as Adjuvant Treatment for Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer: Results from the Global Phase III lidERA Breast Cancer Trial. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract GS1-10.","DOI":"10.1158\/1557-3265.SABCS25-GS1-10"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2025.43.16_suppl.505","article-title":"SOFT and TEXT Investigators, IBCSG, BIG and North American BC Groups. 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS","volume":"43","author":"Francis","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S1556","DOI":"10.1016\/j.annonc.2025.09.021","article-title":"Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2\u2013positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05 [LBA abstract]","volume":"36","author":"Geyer","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): A randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"LBA500","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA500","article-title":"De-Escalated Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab with or Without Carboplatin in HER2-Positive Early Breast Cancer (neoCARHP): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"43","author":"Gao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO-25-01153","article-title":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial","volume":"44","author":"Li","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.annonc.2025.02.011","article-title":"Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: A randomized, open-label, phase II trial","volume":"36","author":"Li","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lambertini, M., Samy, F., Agostinetto, E., Arecco, L., Freire, P., Sonnenblick, A., Arpino, G., Del Mastro, L., Choudhury, A., and Harbeck, N. (2025, January 9\u201312). Adjuvant Aromatase Inhibitor or Tamoxifen in Patients with Hormone Receptor-Positive\/HER2-Positive Early Breast Cancer: An Exploratory Analysis from the ALTTO (BIG 2-06) Trial. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract GS1-03.","DOI":"10.1158\/1557-3265.SABCS25-GS1-03"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1016\/j.annonc.2025.08.721","article-title":"292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial","volume":"36","author":"Loibl","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMc2416491","article-title":"Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"392","author":"Neven","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Schmid, P., Cortes, J., Pusztai, L., McArthur, H., K\u00fcmmel, S., Denkert, C., Park, Y.H., Hui, R., Harbeck, N., and Takahashi, M. (2025, January 9\u201312). Pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage TNBC: A post hoc analysis of participants included and separately of those not included in the first interim analysis for pCR in the KEYNOTE-522 study. Presented at the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Presentation number PS4-07-27.","DOI":"10.1158\/1557-3265.SABCS25-PS4-07-27"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.annonc.2025.08.752","article-title":"323MO Efficacy of adjuvant anti-PD-L1 avelumab by tumor infiltrating lymphocytes (TILs) for high-risk triple negative breast cancer in the phase III A-BRAVE trial","volume":"36","author":"Dieci","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S1560","DOI":"10.1016\/j.annonc.2025.09.025","article-title":"LBA15 Low Dose Pembrolizumab in Addition to Neoadjuvant Anthracycline and Taxane in Triple-Negative Breast Cancer: A Randomized Controlled Trial","volume":"36","author":"Batra","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_25","first-page":"JCO.2025.12350","article-title":"Long-term outcomes of carboplatin added to adjuvant dose-dense chemotherapy for high-risk triple-negative breast cancer (NRG-BR003): A randomized, phase 3 trial","volume":"43","author":"Geyer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Felsheim, B.M., Nekljudova, V., Carey, L.A., Huober, J., Schneeweiss, A., Tolaney, S.M., Untch, M., Kuzma, C.S., Fernandez-Martinez, A., and Rachakonda, S. (2025, January 9\u201312). Pooled Analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto Clinical Trials Identifies the Impact of Neoadjuvant Carboplatin on pCR and Survival in Early-Stage Triple-Negative Breast Cancer. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract RF2-02.","DOI":"10.1158\/1557-3265.SABCS25-RF2-02"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, X., Huang, J., Shi, H., Zhu, J., Wu, W., Ye, G., He, Q., Shi, Y., Zhang, A., and Xie, X. (2025, January 9\u201312). Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes with or Without Carboplatin for Early Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Controlled Phase III Trial. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract RF2-03.","DOI":"10.1158\/1557-3265.SABCS25-RF2-03"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, Y., Gong, Y., Zhu, X., Liu, G., Yu, K., Yang, F., Chen, L., He, M., Hu, Z., and Chen, C. (2025, January 9\u201312). Effect of Adjuvant Carboplatin Intensified Chemotherapy Versus Standard Chemotherapy on Survival in Women with High-Risk Early-Stage Triple-Negative Breast Cancer (CITRINE): A Phase 3 Randomized Trial. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract RF2-04.","DOI":"10.1158\/1557-3265.SABCS25-RF2-04"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mayer, E.L., Timms, K.M., Abramson, V.G., Tung, N.M., Patel, T., Burgess, E.F., DeMeo, M.K., DiNome, M.L., Elias, A.D., and Gatti-Mays, M.E. (2025, January 9\u201312). TBCRC-056: Phase II Study of Neoadjuvant Niraparib + Dostarlimab in Germline *BRCA1\/2* or PALB2 Mutated, HER2-Negative Breast Cancer. Presented at the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract RF5-02.","DOI":"10.1158\/1557-3265.SABCS25-RF5-02"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tung, N., Stradella, A., Brufsky, A., Fasching, P.A., Garc\u00eda-S\u00e1enz, J.A., Paluch-Shimon, S., Henao Carrasco, F.M., Marquez Aragones, A., Park-Simon, T.-W., and Antolin Novoa, S. (2025, January 9\u201312). OlympiAN: A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab in Patients with BRCA Mutations and Early-Stage HER2-Negative Breast Cancer. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract RF5-03.","DOI":"10.1158\/1557-3265.SABCS25-RF5-03"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2025.43.16_suppl.511","article-title":"A phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab (SG\/P) in Patients with Early-Stage Triple-Negative Breast Cancer: Results from the NeoSTAR Trial","volume":"43","author":"Abelman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S1470-2045(25)00545-5","article-title":"Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): Updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial","volume":"26","author":"Yuan","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"LBA1008","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","article-title":"Trastuzumab Deruxtecan (T-DXd) + Pertuzumab (P) vs Taxane + Trastuzumab + Pertuzumab (THP) for First-Line (1L) Treatment of Patients (pts) with Human Epidermal Growth Factor Receptor 2\u2013Positive (HER2+) Advanced\/Metastatic Breast Cancer (a\/mBC): Interim Results from DESTINY-Breast09","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","volume":"394","author":"Tolaney","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hamilton, E., Curigliano, G., Martin, M., Lerebours, F., Tsurutani, J., Savard, M., Jerzak, K., Hu, X., de Aquino Pimentel, L.M., and O\u2019Sullivan, C. (2025, January 9\u201312). HER2CLIMB-05: A Randomized, Double-Blind, Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract GS1-01.","DOI":"10.1158\/1557-3265.SABCS25-GS1-01"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Song, E., Yao, H., Li, H., Yin, Y., Zhang, Q., Wang, S., Ouyang, Q., Sun, T., Wang, X., and Xie, W. (2025, January 9\u201312). SHR-A1811 Versus Pyrotinib Plus Capecitabine in Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced\/Metastatic Breast Cancer (BC): A Multicenter, Open-Label, Randomized, Phase III Study (HORIZON-Breast01). Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract LBA19.","DOI":"10.1016\/j.annonc.2025.09.029"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhang, T., Xu, J., Yin, J., Gao, Y., Zheng, H., Fu, B., Sun, J., Xu, Z., Tu, S., and Mao, Y. (2025). SHR-A1811, a novel anti-HER2 antibody\u2013drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0326691"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1016\/j.annonc.2025.08.909","article-title":"485MO Health-Related Quality of Life (HRQoL) from the PATINA Trial (AFT-38): Impact of Adding Palbociclib to HER2 and Endocrine Therapy (ET) after Induction in HR+\/HER2+ Metastatic Breast Cancer (MBC)","volume":"36","author":"Mazza","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: Long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-024-03462-0","article-title":"Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: A phase 2 basket trial","volume":"31","author":"Okines","year":"2025","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"105852","DOI":"10.1016\/j.esmoop.2025.105852","article-title":"Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: Results from an open-label, multicenter, phase Ib\/II study","volume":"10","author":"Wang","year":"2025","journal-title":"ESMO Open"},{"key":"ref_42","first-page":"S3","article-title":"Primary Results from ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan vs Chemotherapy in Patients with Previously Untreated Metastatic Triple-Negative Breast Cancer Who Are Unable to Receive PD-(L)1 Inhibitors","volume":"36","author":"Bardia","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Punie, K., Tolaney, S.M., Bardia, A., Hurvitz, S.A., Barrios, C., Schneeweiss, A., Sohn, J., Tokunaga, E., Brufsky, A., and Park, Y.H. (2025, January 9\u201312). Patient-Reported Outcomes (PROs) with Sacituzumab Govitecan (SG) vs Chemotherapy in Patients with Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Not Candidates for PD-(L)1 Inhibitors in the Phase 3 ASCENT-03 Study. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract RF6-05.","DOI":"10.1158\/1557-3265.SABCS25-RF6-05"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.annonc.2025.08.978","article-title":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced\/metastatic triple-negative breast cancer: Results from arms 7 and 8 of the phase 1b\/2 BEGONIA study","volume":"36","author":"Schmid","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_45","first-page":"285","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival analysis of the phase III TROPION-Breast01 study","volume":"43","author":"Pistilli","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(25)00523-6","article-title":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): Interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.annonc.2025.08.911","article-title":"Overall survival with first versus second-line use of CDK4\/6 inhibitors in HR+\/HER2\u2212 advanced breast cancer: Results from the phase 3 SONIA trial (BOOG 2017-03)","volume":"36","author":"Wortelboer","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S1569","DOI":"10.1016\/j.annonc.2025.09.035","article-title":"LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+\/HER2\u2212 advanced breast cancer: A phase III trial (CULMINATE-2)","volume":"36","author":"Song","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.annonc.2025.08.910","article-title":"486MO Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4\/6 inhibitor (CDK4\/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+\/HER2\u2212 advanced breast cancer (ABC)","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.annonc.2025.08.912","article-title":"489MO Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+\/human epidermal growth factor receptor 2 (HER2): Advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial","volume":"36","author":"Campone","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S1561","DOI":"10.1016\/j.annonc.2025.09.026","article-title":"Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2\u2212 aBC) previously treated with a CDK4\/6 inhibitor (i): Primary results of the phase III evERA BC trial [LBA abstract]","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_56","first-page":"1189","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial","volume":"392","author":"Jhaveri","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Pistilli, B., Layman, R., Curigliano, G., Andr\u00e9, F., Cristofanilli, M., Mart\u00edn, M., Wesolowski, R., Kim, S.-B., Kim, G., and Richardet, M. (2025, January 9\u201312). Gedatolisib, a Multi-Target PI3K\/AKT\/mTOR (PAM) Inhibitor, Plus Fulvestrant with or Without Palbociclib for Second-Line (2L) Treatment of Patients with HR+\/HER2-\/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results from the Randomized, Phase 3 VIKTORIA-1 Trial. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Abstract RF7-04.","DOI":"10.1158\/1557-3265.SABCS25-RF7-04"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102980","DOI":"10.1016\/j.ctrv.2025.102980","article-title":"Overcoming Resistance to CDK4\/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies","volume":"139","author":"Giugliano","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-24-2740","article-title":"First-in-Human Phase I\/IIa Study of the First-in-Class CDK2\/4\/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer","volume":"31","author":"Yap","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"116101","DOI":"10.1016\/j.ejca.2025.116101","article-title":"Letrozole to prevent breast cancer in postmenopausal women with BRCA1\/2 mutations (LIBER study)","volume":"231","author":"Pujol","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1016\/j.annonc.2025.08.779","article-title":"350P Long-term gynaecological safety and benign breast disease on low-dose tamoxifen: 10-year results from the TAM-01 phase III trial","volume":"36","author":"Carbone","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-24-4221","article-title":"Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+\/HER2\u2212 Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial","volume":"31","author":"Guiu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1\u2013or BRCA2 -Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.23.02112","article-title":"US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer","volume":"42","author":"Shah","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1971\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:52:24Z","timestamp":1771491144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041971"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041971","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}